Human cell and data bank to study neurodegenerative diseases
Official title: The NINDS Human Cell and Data Repository (U24 renewal)
Funded at Rutgers, the State Univ of N.j. · NIH-11392944 · Data updated 2026-11-12
A national repository collects and shares patient-derived cells and data to help researchers understand and treat diseases like Alzheimer’s, ALS, and related conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers, the State Univ of N.j. NIH-funded |
| Lab location | 1 site (Piscataway, United States) |
| Project start | September 30, 2015 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,339,262 |
| NIH project number | 5U24NS095914-12 |
| Project ID | NIH-11392944 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include adults with Alzheimer’s disease dementia, Alzheimer’s-related conditions, or ALS/MND who may participate by contributing biological samples or data for research.
✕Less likely to help
People not contributing samples or data or those without neurodegenerative conditions may not directly benefit.
What this research studies
This grant supports a central biorepository that collects, derives, and distributes human cells and associated data from people with neurodegenerative diseases. Researchers can use hiPSCs and isogenic cell lines to model disease in a dish, screen drugs, and study how genetic background influences disease. The program emphasizes standardized protocols, quality control, and broad data access to accelerate discoveries that could lead to better therapies. It also aims to provide researchers with curated resources that reflect real patient diversity, improving the relevance of laboratory findings to patients.
Why it matters
Potential benefit: If successful, the repository could speed the discovery of effective treatments by providing high-quality human cell models and data.
How similar studies have gone: Previous hiPSC-based models and CRISPR-edited isogenic lines have improved disease understanding and drug screening in neurodegenerative diseases, suggesting this approach is promising.
Where this research is happening
-
Rutgers, the State Univ of N.j.
Piscataway, United States Active
Researchers
- Principal investigator: Knowles, James a — Rutgers, the State Univ of N.j.
- Study coordinator: Knowles, James a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.